• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Domain Therapeutics receives $230K grant from Michael J. Fox Foundation

Domain Therapeutics receives $230K grant from Michael J. Fox Foundation

April 14, 2014
CenterWatch Staff

Domain Therapeutics, a biopharmaceutical company specializing in the R&D of new drug candidates targeting G protein-coupled receptors (GPCRs), has received a second grant of $230,000from the Michael J. Fox Foundation(MJFF) for Parkinson’s research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program. The MJFF first supported the initial stages of this program in 2012 with a $300,000 grant.

Currently, marketed medications regulate only the symptoms of Parkinson’s disease. Although these drugs make patients’ life easier, they are not curative. In this context, Domain has generated an mGluR3 PAM program with the prospect of curing Parkinson’s disease.

“This new grant allows Domain to move forward its mGluR3 PAM program toward in vivo proof-of-concept and identification of a preclinical candidate,” said Pascal Neuville, board director and CEO of Domain Therapeutics. “It also increases our opportunities to meet pharma’s expectations, with the objective of reaching an effective partnership deal to ultimately help those living with Parkinson’s disease and enhance their quality of life.”

Domain discovered that mGluR3 PAMs already demonstrate, in vitro, a neuroprotective effect, mediated by the production of growth factors. Stimulating the production of these growth factors is essential for the survival of neurons. Throughout the rest of this year, Domain will identify the most favorable among its mGluR3 PAM leads in order to conduct proof-of-concept studies in Parkinson’s disease models.

“MJFF is dedicated to finding a cure for Parkinson’s disease, and stimulation of neurotrophic factors is one approach we find promising toward that goal,” said Marco Baptista, associate director of research programs at MJFF. “Our support recognizes the quality of Domain’s mGluR3 PAM program and our confidence in the capacity of the company to progress this valuable asset.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing